Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06114875 · ClinicalTrials.gov registry record · NA
Brief Interventions on Social Media to Reduce Suicide Risk (Intervention 1)
A NA study, sponsored by Harvard University.
- Terminated
- Registry status
- NA
- Development phase
- 942
- Enrollment target
NCT06114875: Clinical Trial NA study, sponsored by Harvard University.
NCT06114875 is a NA study that was terminated before completion, run by Harvard University. The registered enrollment target is 942 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06114875, a NA study, was terminated before completion, sponsored by Harvard University.
- TERMINATED
- Registry status
- NA
- Development phase
- 942 participants
- Enrollment target
Study Summary
This clinical trial is part of a series of brief interventions to reduce suicide risk in collaboration with the social media platform RallyPoint, a site specifically designed for U.S. servicemembers and veterans to connect with one another. In this RCT (Intervention 1: Peer Support), the investigators will test a psychoeducational intervention aimed at increasing peer responses to RallyPoint posts that a machine learning risk algorithm developed by the current team has identified for signs of distress (e.g., descriptions of suicidal thoughts and behaviors or other mental health concerns). In this intervention, the investigators will flag these distressed posts and prompt peers to reply to the posts by providing informational blurbs detailing helpful peer responses.
Primary Outcome
The number of replies participants make to peers' social media posts.
Interventions
- BEHAVIORAL Peer support intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 942 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2025-03-14 |
| Phase | NA |
Why NCT06114875 stopped before completion
NCT06114875 is an interventional study that assigns participants to a tested intervention. The registered 942 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 1 intervention - of which Peer support intervention is the first listed.
NCT06114875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06114875 about?
NCT06114875 is a clinical study titled "Brief Interventions on Social Media to Reduce Suicide Risk (Intervention 1)". This clinical trial is part of a series of brief interventions to reduce suicide risk in collaboration with the social media platform RallyPoint, a site specifically designed for U.S. servicemembers and veterans to connect with one another. In this RCT (Intervention 1: Peer Support), the investigato...
What is the current status of trial NCT06114875?
This trial is currently terminated. It is a NA study. The enrollment target is 942 participants. The study started on 2023-11-20. Estimated completion is 2025-03-14.
What interventions are being tested in trial NCT06114875?
The interventions under investigation include: Peer support intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT06114875?
This trial is sponsored by Harvard University, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06114875's enrollment target sits among peer trials
942 123rd of 2000 higher than 1,878 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI